[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100344931":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":34,"centralContacts":38,"locations":43,"responsibleParty":61,"collaborators":63,"id":67,"slug":33,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":33,"eligibilityCriteria":71,"healthyVolunteers":68,"sex":72,"minAge":73,"maxAge":33,"enrollmentInfo":74,"targetDuration":33,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":33,"overallStatus":46,"whyStopped":33,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Yale University","OTHER",[8,14,19,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with hereditary hypophosphatemic rickets with HHRH","EXPERIMENTAL","Hereditary hypophosphatemic rickets with hypercalciuria (HHRH)",[13],"Drug: phosphate",{"label":15,"type":16,"description":17,"interventionNames":18},"Patients with X-linked Hypophosphatemia","ACTIVE_COMPARATOR","Patients with X-linked hypophosphatemia",[13],{"label":20,"type":16,"description":21,"interventionNames":22},"15 Patients with X-linked Hypophosphatemia","15 Patients with X-linked Hypophosphatemia that will receive phosphate treatment for 30 days.",[13],{"label":24,"type":16,"description":25,"interventionNames":26},"15 Patients Hereditary hypophosphatemic rickets with HHRH","15 patients withHereditary hypophosphatemic rickets with hypercalciuria (HHRH) that will receive phosphate treatment for 30 days.",[13],[28],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"DRUG","phosphate","The target daily phosphate (Pi) intake is 3,500 mg\u002Fday (dietary intake plus our supplementation) for this study. Subjects will take a supplement of Pi (as KPhos Neutral 250 mg\u002Ftablet) to reach this target. Subjects will receive treatment for 30 days.",[24,20,15,9],null,[35],{"name":36,"affiliation":5,"role":37},"Clemens Bergwitz, MD","PRINCIPAL_INVESTIGATOR",[39],{"name":36,"role":40,"phone":41,"phoneExt":33,"email":42},"CONTACT","203-737-5450","clemens.bergwitz@yale.edu",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Yale University School of Medicine","RECRUITING","New Haven","Connecticut","06511","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-72.92816,41.30815,{"lat":56,"lon":55},[59],{"name":60,"role":40,"phone":41,"phoneExt":33,"email":42},"Clemens Bergwitz, M.D.",{"type":62,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR",[64],{"name":65,"class":66},"National Center for Advancing Translational Sciences (NCATS)","NIH","100344931",false,"NCT03771105","The Impact of Phosphate Metabolism on Healthy Aging","Inclusion Criteria:\n\n* Children above the age of 13 years\n* Younger and older adults with XLH and HHRH with confirmed NPT2c mutations affecting both copies of the NPT2c gene (HHRH) or one copy of the PHEX gene (XLH)\n* Be willing to provide access to prior medical records to determine eligibility including imaging, biochemical, medical, and surgical history data\n* Be willing and able to complete all aspects of the study\n* Be willing to adhere to the study visit schedule and comply with the assessments (in the opinion of the investigator).\n\nExclusion Criteria:\n\n* Subjects will be excluded, if they are children younger than age 13 years\n* Subjects that have other diseases likely to impact bone and mineral metabolism (e.g. renal, hepatic, gastrointestinal disorders, and malignancy),\n* Subjects that are currently pregnant,\n* Subjects that received medical therapy or developed any condition, which in the opinion of the investigator, could present a concern for either subject safety or difficulty with data interpretation.\n* Subjects will be excluded from Aim 2, if they are unable to tolerate supplemental phosphate.","ALL","13 Years",{"count":75,"type":76},30,"ESTIMATED","INTERVENTIONAL",[79],"EARLY_PHASE1","Determine the association between duration and dose of chronic conventional therapy with Pi and renal (nephrocalcinosis\u002Fnephrolithiasis), vascular (endothelial function), and cardiovascular function (echo- cardiography) in patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH) and patients with X-linked hypophosphatemia (XLH).",[82,83,84,85,86],"Hypophosphatemia","Rickets","Hypercalciuria","XLH","HHRH","2026-05-21",{"date":89,"type":90},"2026-05-27","ACTUAL",{"date":92,"type":90},"2019-01-01",{"date":94,"type":76},"2028-04",{"name":5,"class":6},1]